《新股消息》北交所上市公司康樂衛士申請赴港上市 料成首隻「北+H」新股
北交所上市公司北京康樂衛士生物技術(833575.BJ)向聯交所提交主板上市申請,聯席保薦人中信証券及建銀國際。
根據康樂衛士去年底於北交所公布,該公司擬申請發行不低於約4,957.76萬股H股新股,即不低於發行後公司總股本15%,並將依市場情況授予承銷商不超過前述發行的H股股數15%的超額配售權,在全額行使15%超額配售權的情況下,預料合共發行不少於約5,701.43萬股H股新股,佔發行後總股本16.87%。
初步招股文件顯示,北京康樂衛士為中國臨床階段的疫苗開發商,目前正從生物技術研發向商業化轉型,旗下擁有9種重組疫苗及mRNA疫苗產品,當中包括接近商業化階段的三價HPV候選疫苗,預料將於今年內提交生物製品許可證申請。
截至去年9月底止首三季,公司尚未錄得盈利,亦未開始商業化生產及疫苗銷售,期內虧損近2.25億元人民幣,對比2022年同期虧損則為2.1億元人民幣。(gc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.